Synopsis: Shares of Gaudium IVF and Women Health Limited listed at ₹83 on the NSE and BSE today, February 27, 2026, marking a 5.06% premium over the issue price of ₹79. While the listing was modest compared to recent SME blockbusters, it reflects stable investor confidence in India’s first pure-play listed fertility services provider.

---

Gaudium IVF Listing Premium: Shares Debut at ₹83 With 5% Gains

The healthcare sector’s latest entrant, Gaudium IVF, successfully transitioned to the public markets today. Despite a muted opening in the broader Nifty50 index, which was trading in the red, the stock managed to hold its ground.

The listing aligns closely with recent Grey Market Premium (GMP) trends. The GMP had cooled from double digits to around ₹4–₹5 per share ahead of the debut.

Listing Performance and Investor Gains

The IPO, which was a ₹165 crore book-built issue, saw a healthy 7.27x overall subscription.

Retail investors, who were allotted shares in lots of 189, saw a modest listing day profit.

Key Listing Data:

• Issue Price: ₹79
• Listing Price: ₹83 (NSE/BSE)
• Intraday High (10:15 AM): ₹83.45
• Profit Per Lot: Approximately ₹756 (at ₹83 listing price)

Fundamental Drivers: Why Investors are Bullish

Analysts maintain a positive long-term outlook on the stock, citing the company’s industry-leading 40% EBITDA margins. They also highlight its strategic position in the rapidly expanding assisted reproductive technology (ART) market.

• Hub-and-Spoke Model: The company’s asset-light model, consisting of 7 central hubs and 28 spokes, allows for high scalability into Tier-2 and Tier-3 cities.
• Clinical Excellence: With a reported success rate of 58.74%—significantly higher than the industry average of 45%—Gaudium has established a strong brand moat.
• Proceeds Utilization: The ₹90 crore fresh issue capital will primarily fund the establishment of 19 new IVF centers, aiming to triple the company’s geographic footprint by FY28.

Also Read: Why Home First Finance Shares Fell 6% After ₹663 Crore Block Deal

Risk Factors to Watch

While the listing was positive, some brokerages remain cautious due to high contingent liabilities and significant regional concentration, with over 78% of revenue currently originating from the Delhi-NCR hub.

Additionally, the fertility sector faces high employee attrition (63% in FY25), making the retention of skilled embryologists a critical operational challenge.

Investors with a 2–3 year horizon may find value in holding the stock, as the Indian IVF market is projected to grow at a 13.1% CAGR through 2034.

Disclaimer: The views expressed are for informational purposes only and do not constitute financial advice. Investing in stocks and IPOs involves significant risk.

forgeup.in is not liable for any financial losses. Always consult a certified investment advisor before making any decisions.